摘要
目的:探讨正常晚期妊娠妇女血生化指标的特点,更好地辅助临床诊断和治疗。方法:测定并比较92例正常晚期妊娠妇女和65例健康非妊娠妇女的15项血生化指标。结果:正常晚期妊娠组与健康非妊娠对照组相比,总蛋白(TP)、白蛋白(ALB)、碱性磷酸酶(ALP)、α-L-岩藻糖苷酶(AFU)、总胆汁酸(TBA)共5项指标均有非常显著性差异(P<0.01),血糖(GLU)、肌酐(CR)等2项指标有显著性差异(P<0.05),而总胆红素(TBIL)、谷丙转氨酶(ALT)、γ-谷氨酰转肽酶(GGT)、谷草转氨酶(AST)、肌酸激酶(CK)、乳酸脱氢酶(LDH)、尿素氮(BUN)、尿酸(UA)共8项指标2组间比较均无统计学意义(P>0.05)。结论:正常晚期妊娠时,孕妇血TP、ALB、ALP、AFU、TBA、GLU及CR等7项指标的改变由妊娠适应性生理反应引起,非机体组织器官疾患所致,该7项指标已不适于以健康未妊娠妇女的正常参考值范围作为衡量标准,提示临床医护人员分析晚期妊娠妇女血生化指标时应结合多项相关指标甚至多种辅助检查结果进行,以便及时制定正确合理的诊疗策略。
Objective：To investigate the characteristics for the blood biochemical indicators of normal late trimester pregnancy women,in order to better assist the clinical diagnosis and treatment.Methods：15 blood biochemical indicators of 92 normal late pregnancy women and 65 healthy non-pregnant women were determined and compared.Results：Through comparison between normal late pregnancy group and the healthy non-pregnant control group,it was found that for the five indicators of total protein（TP）,albumin（ALB）,alkaline phosphatase（ALP）,α-L-fucosidase（AFU）,total bile acid（TBA）,there was a highly significant difference respectively（P0.01）,significant difference for the two indictors of glucose（GLU） and creatinine（CR）（P0.05）,whereas there was no statistically significant difference between the two groups for the eight indicators of total bilirubin（TBIL）,alanine aminotransferase（ALT）,γ-glutamyltranspeptidase（GGT）,aspartate aminotransferase（AST）,creatine kinase（CK）,lactate dehydrogenase（LDH）,blood urea nitrogen（BUN）,uric acid（UA）（P0.05）.Conclusion：At the normal late pregnancy time,the changes occurring to the seven serum indicators of TP,ALB,ALP,AFU,TBA,GLU and CR among pregnant women are caused by the body＇s physiological adaptation to pregnancy,rather than disease of body tissues and organs.Hence the seven indicators are not suitable to be considered with normal reference values range of healthy non-pregnant women.It is suggested that to analyze serum biochemical indicators of late pregnancy women,clinical staff should take into consideration a number of related indicators or a variety of ancillary test results,so as to develop a timely,correct and reasonable treatment strategy.
出处
《生物技术通讯》
CAS
2011年第3期424-427,共4页
Letters in Biotechnology
